FDA Approves First New Molecular Entity Under National Priority Voucher Program

01 Apr 20264 min read0 views

GIST

The U.S. Food and Drug Administration today approved Foundayo (orforglipron) marking the fifth approval under the Commissioner's National Priority Voucher (CNPV) pilot program.

Clinical Editorial

Summary

FDA News Releases published a clinical update in Research Highlights on 01 Apr 2026. The item focuses on FDA Approves First New Molecular Entity Under National Priority Voucher Program. Open the detail page to review the full original feed content.